Traduction de «continued to benefit from » (Néerlandais → Français) :

All regions continued to benefit from the product portfolio rejuvenation, particularly Europe (USD 2.7 billion, +8% cc), generating 27% of its net sales from recently launched products.
Toutes les régions ont continué de bénéficier du rajeunissement du portefeuille de produits, en particulier l’Europe (USD 2,7 milliards, +8% tcc) dont 27% du chiffre d’affaires net proviennent de ces nouveaux produits.

All regions continued to benefit from the product portfolio transformation, particularly Europe (USD 2.8 billion, +10% cc) generating 25% of its net sales from recently launched products.
Toutes les régions ont bénéficié de la transformation du portefeuille de produits, en particulier l’Europe (USD 2,8 milliards, +10% tcc) dont 25% du chiffre d’affaires net provient de produits lancés récemment.

Gains were also seen in the US (USD 2.5 billion, +12% lc), while Japan (USD 889 million, +9% lc) continued to benefit from new launches in 2009.
Les Etats-Unis (USD 2,5 milliards, +12% en m. l) ont également progressé alors que le Japon (USD 889 millions, +9% en m. l) a continué de tirer profit des lancements effectués en 2009.

Q3 2009 Q3 2008 Change USD m USD m USD m Net income from continuing operations 2 112 2 082 30 Fair value adjustments on financial instruments, net of taxes 124 –221 345 Net actuarial losses from defined benefit plans, net of taxes –733 –790 57 Novartis share of equity recognized by associated companies, net of taxes 37 –176 213
T3 2009 T3 2008 Variation M USD M USD M USD Résultat net des activités poursuivies 2 112 2 082 30 Ajustement des instruments financiers à leur juste valeur, nets d’impôts 124 –221 345

2009 2008 Change USD m USD m USD m Net income from continuing operations 8 454 8 163 291 Fair value adjustments on financial instruments, net of taxes 93 –510 603 Net actuarial gains/losses from defined benefit plans, net of taxes 949 –2 140 3 089
T4 2009 T4 2008 Variation M USD M USD M USD Résultat net des activités poursuivies 2 323 1 507 816 Variation de juste valeur sur instruments financiers, nette d'impôts –67 –212 145

H1 2009 H1 2008 Change USD m USD m USD m Net income from continuing operations 4 019 4 574 –555 Fair value adjustments on financial instruments, net of taxes 36 –77 113 Net actuarial losses from defined benefit plans, net of taxes –55 –158 103 Novartis share of equity recognized by associated companies, net of taxes –86 –13 –73
Part de Novartis aux capitaux propres comptabilisée par les sociétés associées, nette d’impôts –86 –13 –73 Effets des écarts de conversion 12 1 365 –1 353 Montants liés aux activités abandonnées 9 –9 Produits et charges comptabilisés au bilan 3 926 5 700 –1 774 Attribuable aux: Actionnaires de Novartis AG 3 896 5 691 –1 795

Q2 2009 Q2 2008 Change USD m USD m USD m Net income from continuing operations 2 044 2 266 –222 Fair value adjustments on financial instruments, net of taxes 79 13 66 Net actuarial gains from defined benefit plans, net of taxes 610 506 104 Novartis share of equity recognized by associated companies, net of taxes –19 –19
Part de Novartis aux capitaux propres comptabilisée par les sociétés associées, nette d’impôts –19 –19 Effets des écarts de conversion 1 415 –11 1 426 Montants liés aux activités abandonnées –6 6 Produits et charges comptabilisés au bilan 4 129 2 768 1 361 Attribuable aux: Actionnaires de Novartis AG 4 108 2 764 1 344

Table 2: Search for additional RCTs Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for RCT’s Date 27/04/2010 Keywords Breast neoplasms (MESH), mass screening (or early detection) (MESH), mammography (MESH) Medline 1 Randomized controlled trials/ (66083) Medline (OVID): (OVID): 2 Randomized controlled trial.pt (289038) Filter Filter 3 Random allocation/ (67885) RCT RCT 4 Double blind method/ (105956) 5 Single blind method/ (13834) 6 Clinical trial.pt (460563) 7 exp clinical trial/ (606505) 8 or/1-7 (718664) 9 (clinic$ adj trial$).tw (146686) 10 ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw (105209) 11 Placebos/ (28712) 12 Placebo$.tw (125428) 13 Randomly allocated.tw (12231) 14 (allocated adj2 random).tw (654) 15 9 or 10 or 11 or 12 or 13 or 14 (312732) 16 8 or 15 (842155) 17 Case report.tw (155883) 18 Letter.pt (688664) 19 Historical article.pt (263287) 20 Review of reported cases.pt (0) 21 Review,multicase.pt (0) 22 17 or 18 or 19 or 20 or 21 (1098644) 23 16 not 22 (822810) 24 Breast/ or Breast Diseases/ (30717) 25 Neoplasms/ (216644) 26 24 and 25 (535) 27 (breast$ adj5 neoplasm$).tw (1588) 28 (breast$ adj5 cancer$).tw (135654) 29 (breast$ adj5 carcin$).tw (31778) 30 (breast$ adj5 tumo$).tw (23438) 31 (breast$ adj5 metasta$).tw (16580) 32 (breast$ adj5 malig$).tw (7361) 33 exp Breast Neoplasms/ (171606) 34 exp Carcinoma, Ductal, Breast/ (8460) 35 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 (207174) 36 mammography.mp (23598) 37 screening.mp (274211) 38 36 or 37 (288429) 39 23 and 35 and 38 (2326) 40 limit 39 to (yr=" 2008 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (241) 41 from 40 keep 1-241 (241) 42 from 41 keep 1-241 (241) CENTRAL Breast neoplasms (MESH) and early detection (MESH) or 61 mammography (MESH) (manual limit 2008-2010) in title , abstracts or key words
Table 4: Search for additional RCTs Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for RCT’s Date 27/04/2010 Keywords Breast neoplasms (MESH), mass screening (or early detection) (MESH), mammography (MESH) Medline 1 Randomized controlled trials/ (66083) Medline (OVID): (OVID): 2 Randomized controlled trial.pt (289038) Filter Filter 3 Random allocation/ (67885) RCT RCT 4 Double blind method/ (105956) 5 Single blind method/ (13834) 6 Clinical trial.pt (460563) 7 exp clinical trial/ (606505) 8 or/1-7 (718664) 9 (clinic$ adj trial$).tw (146686) 10 ((singl$ or doubl$ or treb$ or tripl$) adj (blind$3 or mask$3)).tw (105209) 11 Placebos/ (28712) 12 Placebo$.tw (125428) 13 Randomly allocated.tw (12231) 14 (allocated adj2 random).tw (654) 15 9 or 10 or 11 or 12 or 13 or 14 (312732) 16 8 or 15 (842155) 17 Case report.tw (155883) 18 Letter.pt (688664) 19 Historical article.pt (263287) 20 Review of reported cases.pt (0) 21 Review,multicase.pt (0) 22 17 or 18 or 19 or 20 or 21 (1098644) 23 16 not 22 (822810) 24 Breast/ or Breast Diseases/ (30717) 25 Neoplasms/ (216644) 26 24 and 25 (535) 27 (breast$ adj5 neoplasm$).tw (1588) 28 (breast$ adj5 cancer$).tw (135654) 29 (breast$ adj5 carcin$).tw (31778) 30 (breast$ adj5 tumo$).tw (23438) 31 (breast$ adj5 metasta$).tw (16580) 32 (breast$ adj5 malig$).tw (7361) 33 exp Breast Neoplasms/ (171606) 34 exp Carcinoma, Ductal, Breast/ (8460) 35 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 (207174) 36 mammography.mp (23598) 37 screening.mp (274211) 38 36 or 37 (288429) 39 23 and 35 and 38 (2326) 40 limit 39 to (yr=" 2008 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (241) 41 from 40 keep 1-241 (241) 42 from 41 keep 1-241 (241) CENTRAL Breast neoplasms (MESH) and early detection (MESH) or 61 mammography (MESH) (manual limit 2008-2010) in title , abstracts or key words

There may be a small benefit from higher dosed patches than in lower dosed patches.
There was no difference in effect in trials where the dose was tapered or weaned off, compared to those where withdrawal was abrupt.

„If a doctor acts in accordance with the medical practice now being evolved by the Medical Ethics Committee of the BMA, he will be acting with the benefit of guidance from a responsible and competent body of relevant professional opinion.‰
ÿ If a doctor acts in accordance with the medical practice now being evolved by the Medical Ethics Committee of the BMA, he will be acting with the benefit of guidance from a responsible and competent body of relevant professional opinion. Ÿ